Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
AtaiBeckley seen as key beneficiary of Spravato’s strong growth: Jefferies
07:58am, Wednesday, 21'st Jan 2026
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful...
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
11:28am, Monday, 19'th Jan 2026
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key pred
AtaiBeckley shares clinical and preclinical data at ACNP Annual Meeting
09:24am, Friday, 16'th Jan 2026
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
07:00am, Friday, 16'th Jan 2026
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by d
New Strong Sell Stocks for Jan. 13
05:05am, Tuesday, 13'th Jan 2026
ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Mesoblast reports $US35.1m in gross revenue from sales of its cell therapy Ryoncil
05:14am, Friday, 09'th Jan 2026
Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) reported $US35.1 million ($52.4 million) in gross revenue from Ryoncil sales in the December quarter, up 60% on the...
AtaiBeckley issues 2026 outlook, flags multiple clinical milestones
08:59am, Thursday, 08'th Jan 2026
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has outlined its outlook for 2026, highlighting anticipated clinical milestones and recent corporate developments ahead of its participation in the JP Morgan 44
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
07:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes b
AtaiBeckley completes redomiciliation from Netherlands to US
08:31am, Wednesday, 31'st Dec 2025
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delawar
UiPath to be added to S&P MidCap 400, shares jump
04:32am, Wednesday, 24'th Dec 2025
UiPath Inc (NYSE:PATH) shares jumped 6% on the news that the automation platform will be added to the S&P MidCap 400 prior to the opening of trading on...
AtaiBeckley joins the Nasdaq Biotechnology Index
08:40am, Tuesday, 23'rd Dec 2025
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22. The NBI is designed t
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
07:00am, Tuesday, 23'rd Dec 2025
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform pa
AtaiBeckley receives new US patent for oral R-MDMA formulation EMP-01
09:16am, Thursday, 11'th Dec 2025
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that the US Patent and Trademark Office has granted a new patent covering EMP-01, its oral R-MDMA formulation. The company said that the patent inclu
Nasdaq tumbles as AI stocks retreat after Oracle earnings
04:55am, Thursday, 11'th Dec 2025
9.55am: AI and semiconductors lead Nasdaq lower at open Investors moved money out of US tech stocks on Thursday. It was a mixed picture overall on Wall...
Enhanced Fortifies Executive Leadership Team & Board of Directors
07:32pm, Wednesday, 19'th Nov 2025
– Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya
